ResearcherMax Planck Institute of Molecular PhysiologyActive in the last 2 years
Angela Ragone
Matched on ORCID iD 0000-0001-9229-4146; OpenAlex author ID A5030512956.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 3
2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Parameter-Dependent Electroporation and Cellular Responses Induced by Microsecond Pulsed Electric Fields: Different Sensitivity of Two Pancreatic Ductal Adenoc… Co-author DOI 10.3390/bioengineering13091056↗
- AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance? Co-author DOI 10.20517/cdr.2022.34↗
- Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines. First author DOI 10.3389/fphar.2022.837503↗
Closest collaborators
The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Luigi Sapio · 3 shared papers, 2022–2026
- Paper Parameter-Dependent Electroporation and Cellular Responses Induced by Microsecond Pulsed Electric Fields: Different Sen… DOI 10.3390/bioengineering13091056↗
- Paper AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance? DOI 10.20517/cdr.2022.34↗
- Paper Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines. DOI 10.3389/fphar.2022.837503↗
- Silvio Naviglio · 3 shared papers, 2022–2026
- Paper Parameter-Dependent Electroporation and Cellular Responses Induced by Microsecond Pulsed Electric Fields: Different Sen… DOI 10.3390/bioengineering13091056↗
- Paper AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance? DOI 10.20517/cdr.2022.34↗
- Paper Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines. DOI 10.3389/fphar.2022.837503↗
- Mariateresa Allocca · 1 shared paper, 2026
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.